Siegel R et al. Cancer statistics, 2014. CA. Cancer J. Clin., 2014, 64(1): 9–29.
Ferlay J et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015, 136(5): E359–E386.
Bray F et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer, 2013, 132(5): 1133–1145.
Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Известия Тинро, 2014, 226: 1-226.
Каприн А.Д., Старинский В., Петрова Г.В. Состояние онкологической помощи населению России в 2014 году. 2015.
Бредер В.В. Факторы риска развития гепатоцеллюлярного рака в онкологической практике. Опыт Российского онкологического научного центра им. Н.Н. Блохина Экспериментальная и клиническая гастроэнтерология, 2016, 4: 4–12.
Бредер В.В. Гепатоцеллюлярный рак в Российской Федерации как социальная и медицинская проблема. Медицинский совет, 2016, 10: 10–16.
Kan Z et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res, 2013, 23(23): 1422–1433.
Carlomagno F et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst., 2006, 98(5): 326–334.
Llovet JJM et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4): 378–390.
Cheng A-L et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet. Oncol. Elsevier, 2009, 10(1): 25–34.
Johnson PJ et al. Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. J. Clin. Oncol., 2013, 31(28): 3517–3524.
Abou-Alfa G. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). J Clin Oncol, 2016, 34(suppl 4S): 192.
Zhu AX et al. SEARCH: A Phase III, Randomized, Double-Blind, PlaceboControlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. J. Clin. Oncol., 2015, 33(6): 559–566.
Qin S et al. Randomized, multicenter, openlabel study of oxaliplatin plus fluorouracil/ leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol., 2013, 31(28): 3501–3508.
Cainap C et al. Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. J. Clin. Oncol., 2015, 33(2): 172–179.
Cheng A et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 2011, 29(15_suppl.): 4000.
Cheng A-L et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J. Clin. Oncol., 2017, 35(15_suppl.).
Бисовская Ю.В. et al. Сорафениб в лечении распространенного гепатоцеллюлярного рака: анализ российской и австрийской когорт больных. Клиническая фармакология и терапия, 2014, 23(2): 42–47.
Johnson PJ et al. An assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach -The albi grade. J. Clin. Oncol., 2015, 33(6): 550–558.
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J. Hepatol., 2006, 44(1): 217–231.
Toyoda H et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br. J. Cancer, 2016, 114(7): 744–750.
Бредер В.В. Практические рекомендации по лечению первичного рака печени. Злокачественные опухоли, 2016, 4: 292-299.
Бредер В.В. Стратегия и тактика консервативного лечения гепатоцеллюлярного рака: дис. … д-ра мед. наук. М., 2017. 309 p.
Bruix J et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J. Hepatol. Elsevier, 2017, 57(4): 821–829.
Rahimi RS, Trotter JF. Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence. Ann. Gastroenterol., 2015, 28(3): 323–330.
Miller AA et al. Phase i and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J. Clin. Oncol., 2009, 27(11): 1800–1805.
Arrondeau J et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs, 2012, 30: 2046–2049.
Reiss KA et al. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. J. Clin. Oncol., 2017. DOI: https://doi. org/10.1200/JCO.2017.73.8245..
DOI: 10.1200/JCO.2017.73.8245
Federico A et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol. Lett., 2015, 9(4): 1628–1632.
Lencioni R et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): Second interim analysis. Int. J. Clin. Pract., 2014, 68(5): 609–617.
Estfan B, Byrne MKR. Sorafenib in Advanced Hepatocellular Carcinoma Hypertension as a Potential Surrogate Marker for Efficacy. Am. J. Clin. Oncol., 2013, 36(4): 319–324.
Otsuka T et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol. Res., 2012, 1: 1–8.
Lee S et al. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study. J Gastroenterol Hepato, 2014, 29(7): 1463–1469.
Vincenzi B et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist, 2010, 15(1): 85–92.
Llovet JM et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin. Cancer Res,2012, 18(8): 2290–2300.
Arao T et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology, 2013, 57(4): 1407–1415.
Mancuso MR et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest., American Society for Clinical Investigation, 2006, 116(10): 2610–2621.
Miyahara K et al. Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. Hepatol. Res., 2014, 44(3): 296–301.
Reig M. Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC Refined RECIST. Semin Liver Dis, 2014, 34(4): 445–455.
Schmidt L et al. Addition of Local Hepatic Therapy to Sorafenib in Patients with Advanced Hepatocellular Carcinoma (Stage BCLC C). Digestion, 2014, 90(4): 219–228.
Bruix J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2016, 0(0): 1020–1022.
Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin. Investig. Drugs, 2012, 21(6): 879–889.
Bruix J et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, openlabel, phase II safety study. Eur. J. Cancer., 2013, 49(16): 3412–3419.
Merle P. Updated overall survival analysis and further exploratory analyses from the international, phase 3, randomized, placebocontrolled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment. International Liver Cancer Association 11th Annual Conference, Sept 15–17, 2017 Seoul, Abstract O-031.
Tovar V et al. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut, 2017, 66(3): 530–540.
European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. European Association for the Study of the Liver, 2012, 56(4): 908–943.
Taieb J, Barbare JC, Rougier P. Medical treatments for hepatocellular carcinoma (HCC): What’s next? Ann. Oncol., 2006, 17(Suppl. 10): 308–314.
Edeline J et al. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study. World J. Gastroenterol., 2009, 15(6): 713-716.
Sangro B et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. Elsevier, 2017, 59(1): 81–88.
El-Khoueiry AB et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J. Clin. Oncol., 2015, 33(18_ suppl.): LBA101.
El-Khoueiry AB et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. Elsevier, 2017, 389(10088): 2492–2502.
Terrault NA et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2015.
Xu L. et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J. Gastroenterol. Hepatol., 2015, 30(6): 1032–1039.
EASL Recommendations on Treatment of Hepatitis C 2016. J. Hepatol. European Association for the Study of the Liver, 2016(xxx).
Bornman PC, Krige JE, Terblanche J. Management of oesophageal varices. Lancet (London, England). Elsevier, 1994, 343(8905): 1079–1084.
Garcia-Tsao G et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology, 2007, 46(3): 922–938.
Garcia-Tsao G et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology, 2017, 65(1): 310–335.
Bruix J et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol., 2001, 35(3): 421–430.